These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

879 related articles for article (PubMed ID: 23715499)

  • 21. Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation.
    Hermes M; Geisler H; Osswald H; Riehle R; Kloor D
    Biochem Pharmacol; 2008 Jun; 75(11):2100-11. PubMed ID: 18395186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells.
    Blough MD; Zlatescu MC; Cairncross JG
    Cancer Res; 2007 Jan; 67(2):580-4. PubMed ID: 17234766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.
    Kreth S; Thon N; Eigenbrod S; Lutz J; Ledderose C; Egensperger R; Tonn JC; Kretzschmar HA; Hinske LC; Kreth FW
    PLoS One; 2011 Feb; 6(2):e17156. PubMed ID: 21365007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.
    Wang X; Chen JX; Liu YH; You C; Mao Q
    Neurol Sci; 2013 Aug; 34(8):1421-8. PubMed ID: 23224642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.
    Felsberg J; Thon N; Eigenbrod S; Hentschel B; Sabel MC; Westphal M; Schackert G; Kreth FW; Pietsch T; Löffler M; Weller M; Reifenberger G; Tonn JC;
    Int J Cancer; 2011 Aug; 129(3):659-70. PubMed ID: 21425258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
    Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
    Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
    Kreth S; Limbeck E; Hinske LC; Schütz SV; Thon N; Hoefig K; Egensperger R; Kreth FW
    Acta Neuropathol; 2013 May; 125(5):671-81. PubMed ID: 23340988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study.
    Costa BM; Caeiro C; Guimarães I; Martinho O; Jaraquemada T; Augusto I; Castro L; Osório L; Linhares P; Honavar M; Resende M; Braga F; Silva A; Pardal F; Amorim J; Nabiço R; Almeida R; Alegria C; Pires M; Pinheiro C; Carvalho E; Lopes JM; Costa P; Damasceno M; Reis RM
    Oncol Rep; 2010 Jun; 23(6):1655-62. PubMed ID: 20428822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G
    BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
    Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
    Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
    Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
    Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS
    Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
    Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
    Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
    Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
    Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
    Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
    Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
    Choy KW; Pang CP; To KF; Yu CB; Ng JS; Lam DS
    Invest Ophthalmol Vis Sci; 2002 May; 43(5):1344-9. PubMed ID: 11980845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.